Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tolisign-D
- Development stage
- Unknown
- Lead developer
- Primus Remedies
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tolisign-D is an oral fixed-dose combination product containing tolperisone and diclofenac, developed and marketed by Primus Remedies. Tolperisone is a centrally acting muscle relaxant that functions by inhibiting voltage-gated sodium and calcium channels, thereby stabilizing nerve membranes and suppressing spinal reflexes without the sedative side effects typical of other muscle relaxants. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that provides analgesic and anti-inflammatory activity by inhibiting the cyclooxygenase enzymes COX-1 and COX-2, which are responsible for the synthesis of pro-inflammatory prostaglandins. Tolisign-D is primarily indicated for the management of musculoskeletal pain associated with muscle spasms and inflammatory conditions.
- Brand names
- Tolisign-D
- Other names
- Tolperisone + Diclofenac
02
Targets
CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)CaV (Voltage-gated calcium channel protein complex)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on Tolisign-D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tolisign-D.